Asset Management
Compare Stocks
2 / 10Stock Comparison
CNS vs BLK
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
CNS vs BLK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Asset Management | Asset Management |
| Market Cap | $3.63B | $165.65B |
| Revenue (TTM) | $517M | $20.41B |
| Net Income (TTM) | $164M | $6.10B |
| Gross Margin | 46.8% | 49.4% |
| Operating Margin | 33.4% | 37.1% |
| Forward P/E | 20.8x | 20.1x |
| Total Debt | $141M | $14.22B |
| Cash & Equiv. | $183M | $12.76B |
CNS vs BLK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cohen & Steers, Inc. (CNS) | 100 | 111.9 | +11.9% |
| BlackRock, Inc. (BLK) | 100 | 202.0 | +102.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNS vs BLK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CNS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 2 yrs, beta 0.98, yield 3.3%
- Lower volatility, beta 0.98, Low D/E 24.5%, current ratio 25.39x
- Beta 0.98, yield 3.3%, current ratio 25.39x
BLK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 14.3%, EPS growth 15.1%
- 245.8% 10Y total return vs CNS's 154.3%
- PEG 2.47 vs CNS's 16.52
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.3% NII/revenue growth vs CNS's 5.7% | |
| Value | Lower P/E (20.1x vs 20.8x), PEG 2.47 vs 16.52 | |
| Quality / Margins | Efficiency ratio 0.1% vs CNS's 0.1% (lower = leaner) | |
| Stability / Safety | Beta 0.98 vs BLK's 1.28, lower leverage | |
| Dividends | 3.3% yield, 2-year raise streak, vs BLK's 1.9% | |
| Momentum (1Y) | +18.3% vs CNS's -5.2% | |
| Efficiency (ROA) | Efficiency ratio 0.1% vs CNS's 0.1% |
CNS vs BLK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CNS vs BLK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
BLK leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
BLK is the larger business by revenue, generating $20.4B annually — 39.4x CNS's $517M. Profitability is closely matched — net margins range from 31.2% (BLK) to 29.2% (CNS).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $517M | $20.4B |
| EBITDAEarnings before interest/tax | $198M | $8.3B |
| Net IncomeAfter-tax profit | $164M | $6.1B |
| Free Cash FlowCash after capex | -$94M | $3.9B |
| Gross MarginGross profit ÷ Revenue | +46.8% | +49.4% |
| Operating MarginEBIT ÷ Revenue | +33.4% | +37.1% |
| Net MarginNet income ÷ Revenue | +29.2% | +31.2% |
| FCF MarginFCF ÷ Revenue | +16.4% | +23.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +5.2% | -22.7% |
Valuation Metrics
BLK leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 23.9x trailing earnings, CNS trades at a 6% valuation discount to BLK's 25.4x P/E. Adjusting for growth (PEG ratio), BLK offers better value at 3.13x vs CNS's 19.03x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.6B | $165.7B |
| Enterprise ValueMkt cap + debt − cash | $3.6B | $167.1B |
| Trailing P/EPrice ÷ TTM EPS | 23.94x | 25.42x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.79x | 20.10x |
| PEG RatioP/E ÷ EPS growth rate | 19.03x | 3.13x |
| EV / EBITDAEnterprise value multiple | 19.48x | 20.62x |
| Price / SalesMarket cap ÷ Revenue | 7.01x | 8.12x |
| Price / BookPrice ÷ Book value/share | 6.30x | 3.28x |
| Price / FCFMarket cap ÷ FCF | 42.64x | 35.24x |
Profitability & Efficiency
CNS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
CNS delivers a 28.3% return on equity — every $100 of shareholder capital generates $28 in annual profit, vs $10 for BLK. CNS carries lower financial leverage with a 0.25x debt-to-equity ratio, signaling a more conservative balance sheet compared to BLK's 0.29x. On the Piotroski fundamental quality scale (0–9), BLK scores 6/9 vs CNS's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +28.3% | +9.9% |
| ROA (TTM)Return on assets | +20.5% | +3.7% |
| ROICReturn on invested capital | +19.2% | +9.9% |
| ROCEReturn on capital employed | +22.8% | +5.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.25x | 0.29x |
| Net DebtTotal debt minus cash | -$42M | $1.5B |
| Cash & Equiv.Liquid assets | $183M | $12.8B |
| Total DebtShort + long-term debt | $141M | $14.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 9.27x |
Total Returns (Dividends Reinvested)
BLK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLK five years ago would be worth $13,352 today (with dividends reinvested), compared to $11,824 for CNS. Over the past 12 months, BLK leads with a +18.3% total return vs CNS's -5.2%. The 3-year compound annual growth rate (CAGR) favors BLK at 20.7% vs CNS's 13.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +12.9% | -1.1% |
| 1-Year ReturnPast 12 months | -5.2% | +18.3% |
| 3-Year ReturnCumulative with dividends | +44.3% | +75.7% |
| 5-Year ReturnCumulative with dividends | +18.2% | +33.5% |
| 10-Year ReturnCumulative with dividends | +154.3% | +245.8% |
| CAGR (3Y)Annualised 3-year return | +13.0% | +20.7% |
Risk & Volatility
Evenly matched — CNS and BLK each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNS is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than BLK's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 1.28x |
| 52-Week HighHighest price in past year | $83.99 | $1219.94 |
| 52-Week LowLowest price in past year | $58.39 | $914.84 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +87.5% |
| RSI (14)Momentum oscillator 0–100 | 63.1 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 323K | 790K |
Analyst Outlook
Evenly matched — CNS and BLK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates CNS as "Sell" and BLK as "Buy". Consensus price targets imply 22.8% upside for BLK (target: $1312) vs 6.9% for CNS (target: $76). For income investors, CNS offers the higher dividend yield at 3.29% vs BLK's 1.92%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Sell | Buy |
| Price TargetConsensus 12-month target | $76.00 | $1311.78 |
| # AnalystsCovering analysts | 13 | 33 |
| Dividend YieldAnnual dividend ÷ price | +3.3% | +1.9% |
| Dividend StreakConsecutive years of raises | 2 | 15 |
| Dividend / ShareAnnual DPS | $2.34 | $20.46 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.2% |
BLK leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CNS leads in 1 (Profitability & Efficiency). 2 tied.
CNS vs BLK: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CNS or BLK a better buy right now?
For growth investors, BlackRock, Inc.
(BLK) is the stronger pick with 14. 3% revenue growth year-over-year, versus 5. 7% for Cohen & Steers, Inc. (CNS). Cohen & Steers, Inc. (CNS) offers the better valuation at 23. 9x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate BlackRock, Inc. (BLK) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CNS or BLK?
On trailing P/E, Cohen & Steers, Inc.
(CNS) is the cheapest at 23. 9x versus BlackRock, Inc. at 25. 4x. On forward P/E, BlackRock, Inc. is actually cheaper at 20. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: BlackRock, Inc. wins at 2. 47x versus Cohen & Steers, Inc. 's 16. 52x.
03Which is the better long-term investment — CNS or BLK?
Over the past 5 years, BlackRock, Inc.
(BLK) delivered a total return of +33. 5%, compared to +18. 2% for Cohen & Steers, Inc. (CNS). Over 10 years, the gap is even starker: BLK returned +245. 8% versus CNS's +154. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CNS or BLK?
By beta (market sensitivity over 5 years), Cohen & Steers, Inc.
(CNS) is the lower-risk stock at 0. 98β versus BlackRock, Inc. 's 1. 28β — meaning BLK is approximately 31% more volatile than CNS relative to the S&P 500. On balance sheet safety, Cohen & Steers, Inc. (CNS) carries a lower debt/equity ratio of 25% versus 29% for BlackRock, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CNS or BLK?
By revenue growth (latest reported year), BlackRock, Inc.
(BLK) is pulling ahead at 14. 3% versus 5. 7% for Cohen & Steers, Inc. (CNS). On earnings-per-share growth, the picture is similar: BlackRock, Inc. grew EPS 15. 1% year-over-year, compared to 14. 2% for Cohen & Steers, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CNS or BLK?
BlackRock, Inc.
(BLK) is the more profitable company, earning 31. 2% net margin versus 29. 2% for Cohen & Steers, Inc. — meaning it keeps 31. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BLK leads at 37. 1% versus 33. 4% for CNS. At the gross margin level — before operating expenses — BLK leads at 49. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CNS or BLK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, BlackRock, Inc. (BLK) is the more undervalued stock at a PEG of 2. 47x versus Cohen & Steers, Inc. 's 16. 52x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, BlackRock, Inc. (BLK) trades at 20. 1x forward P/E versus 20. 8x for Cohen & Steers, Inc. — 0. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLK: 22. 8% to $1311. 78.
08Which pays a better dividend — CNS or BLK?
All stocks in this comparison pay dividends.
Cohen & Steers, Inc. (CNS) offers the highest yield at 3. 3%, versus 1. 9% for BlackRock, Inc. (BLK).
09Is CNS or BLK better for a retirement portfolio?
For long-horizon retirement investors, Cohen & Steers, Inc.
(CNS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), 3. 3% yield, +154. 3% 10Y return). Both have compounded well over 10 years (CNS: +154. 3%, BLK: +245. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CNS and BLK?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNS is a small-cap income-oriented stock; BLK is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.